Product Description
Mechanisms of Action: IBAT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Indonesia | Japan | Philippines
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Constipation
Phase 2: Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Constipation|Liver Diseases, Alcoholic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06436833 |
NCT06436833 | N/A |
Recruiting |
Constipation|Weight Loss|Colorectal Cancer|Abdominal Pain|Diarrhea|Chronic Pain|Anemia |
2024-11-30 |
2024-07-30 |
Primary Endpoints |
|
CTR20242115 |
CTR20242115 | N/A |
Completed |
Constipation |
2024-08-03 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240328 |
CTR20240328 | N/A |
Completed |
Constipation |
2024-03-26 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
JapicCTI-184007 |
JapicCTI-184007 | N/A |
Active |
Constipation |
2022-12-01 |
|||
NCT04235205 |
YCU19002 | P2 |
Completed |
Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic |
2021-07-21 |
56% |
2021-11-17 |
|
JapicCTI-205120 |
JapicCTI-205120 | P2 |
Unknown |
Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic |
2021-06-30 |
|||
NCT04006145 |
A3309-012 | P2 |
Completed |
Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2020-06-26 |
29% |
2020-08-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
NCT02392546 |
NCT02392546 | P2 |
Withdrawn |
Constipation |
2016-04-01 |
2019-03-20 |
Treatments |
|
JapicCTI-142608 |
JapicCTI-142608 | P2 |
Completed |
Constipation |
2015-01-01 |
|||
NCT01038687 |
UL1RR024150 | P2 |
Completed |
Constipation |
2011-01-01 |
2020-09-09 |
||
JapicCTI-153061 |
JapicCTI-153061 | P3 |
Completed |
Constipation |
2017-03-31 |
|||
JapicCTI-153062 |
JapicCTI-153062 | P3 |
Completed |
Constipation |
2016-06-30 |
|||
NCT01895543 |
NCT01895543 | P3 |
Completed |
Constipation |
2015-05-01 |
2019-03-19 |
Treatments |
|
2012-005601-46 |
Echo 3 | P3 |
Completed |
Constipation |
2014-12-29 |
2022-03-13 |
Treatments |
|
2012-005587-94 |
Echo 1 | P3 |
Completed |
Constipation |
2014-05-03 |
2022-03-13 |
Treatments |
|
2012-005588-28 |
Echo 2 | P3 |
Terminated |
Constipation |
2014-04-26 |
2022-03-13 |
Treatments |
|
NCT01827592 |
NCT01827592 | P3 |
Terminated |
Constipation |
2014-03-01 |
2019-03-19 |
Treatments |
|
NCT01833065 |
NCT01833065 | P3 |
Terminated |
Constipation |
2014-03-01 |
2019-03-19 |
Treatments |
|
NCT04784780 |
TANK-27 | P4 |
Unknown status |
Constipation |
2023-06-30 |
2025-01-03 |
||
NCT05703464 |
22-Nr-049 | P4 |
Terminated |
Constipation |
2023-03-03 |
2023-03-10 |
Primary Completion Date|Primary Endpoints |
|
NCT05165199 |
R-LODD | P4 |
Unknown status |
Constipation |
2022-09-01 |
2024-03-02 |
Primary Endpoints|Treatments|Trial Status |